First-line aumolertinib plus pemetrexed and carboplatin shows promising ORR and PFS benefit for patients with advanced NSCLC harboring EGFR exon 19 deletion or exon 21 L858R, with an acceptable safety profile. This evidence concerns the gene EGFR and non-small cell lung carcinoma.